Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$13.00 +2.9%	$11.42	$3.98 ▼ $13.40	$1.98B	1.92	2.17 million shs	1.95 million shs
ARQT Arcutis Biotherapeutics	$15.98 +1.2%	$14.71	$8.03 ▼ $17.75	$1.92B	1.84	1.81 million shs	1.41 million shs
BCYC Bicycle Therapeutics	$7.10 +0.1%	$7.71	$6.10 ▼ $28.67	$491.70M	1.44	269,982 shs	210,802 shs
CGON CG Oncology	$26.92 +3.6%	$26.11	$14.80 ▼ $40.47	$2.05B	0.87	717,000 shs	542,477 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	0.00%	-0.31%	+21.95%	+45.58%	+182.00%
ARQT Arcutis Biotherapeutics	0.00%	-5.39%	+6.39%	+14.31%	+91.61%
BCYC Bicycle Therapeutics	0.00%	-4.57%	-17.44%	-11.80%	-68.49%
CGON CG Oncology	0.00%	+4.75%	+2.98%	+5.82%	-26.37%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.4049 of 5 stars	1.4	1.0	4.2	2.0	1.7	0.6
ARQT Arcutis Biotherapeutics	1.7925 of 5 stars	2.4	2.0	0.0	3.4	1.7	0.6
BCYC Bicycle Therapeutics	3.6921 of 5 stars	3.4	4.0	0.0	3.2	4.2	0.6
CGON CG Oncology	1.3761 of 5 stars	3.5	0.0	0.0	2.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	-4.81% Downside
ARQT Arcutis Biotherapeutics	2.86	Moderate Buy	$19.80	23.90% Upside
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$22.22	212.99% Upside
CGON CG Oncology	3.08	Buy	$55.27	105.32% Upside

Current Analyst Ratings Breakdown

Latest BCYC, ARQT, ADPT, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
8/12/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $10.00
8/12/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $13.00
8/11/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$27.00
8/11/2025	BCYC Bicycle Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00 ➝ $44.00
8/7/2025	ARQT Arcutis Biotherapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
7/25/2025	ARQT Arcutis Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$18.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	11.06	N/A	N/A	$1.18 per share	11.02
ARQT Arcutis Biotherapeutics	$196.54M	9.75	N/A	N/A	$1.16 per share	13.78
BCYC Bicycle Therapeutics	$35.28M	13.94	N/A	N/A	$9.66 per share	0.73
CGON CG Oncology	$1.14M	1,800.57	N/A	N/A	$8.79 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	11/6/2025 (Estimated)
ARQT Arcutis Biotherapeutics	-$140.04M	-$0.75	N/A	N/A	N/A	-35.40%	-62.62%	-25.16%	11/5/2025 (Estimated)
BCYC Bicycle Therapeutics	-$169.03M	-$3.51	N/A	N/A	N/A	-1,257.00%	-32.43%	-26.80%	10/30/2025 (Estimated)
CGON CG Oncology	-$88.04M	-$1.77	N/A	N/A	N/A	-15,945.17%	-19.37%	-18.72%	11/11/2025 (Estimated)

Latest BCYC, ARQT, ADPT, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	-$1.14	-$0.19	-$1.14	$9.43 million	$2.90 million
8/8/2025	Q2 2025	CGON CG Oncology	-$0.49	-$0.54	-$0.05	-$0.54	$0.11 million	N/A
8/6/2025	Q2 2025	ARQT Arcutis Biotherapeutics	-$0.18	-$0.13	+$0.05	-$0.13	$72.70 million	$81.50 million
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
ARQT Arcutis Biotherapeutics	0.77	3.20	3.04
BCYC Bicycle Therapeutics	N/A	10.39	10.39
CGON CG Oncology	N/A	22.15	22.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
ARQT Arcutis Biotherapeutics	N/A
BCYC Bicycle Therapeutics	86.15%
CGON CG Oncology	26.56%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
ARQT Arcutis Biotherapeutics	9.40%
BCYC Bicycle Therapeutics	22.90%
CGON CG Oncology	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
ARQT Arcutis Biotherapeutics	150	119.90 million	108.63 million	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
CGON CG Oncology	61	76.25 million	70.61 million	Optionable

BCYC, ARQT, ADPT, and CGON Headlines

Recent News About These Companies

Vanguard Group Inc. Has $142.93 Million Stake in CG Oncology, Inc. $CGON

August 23 at 3:35 AM | marketbeat.com

Fox Run Management L.L.C. Makes New $408,000 Investment in CG Oncology, Inc. $CGON

August 21 at 4:08 AM | marketbeat.com

Piper Sandler Initiates Coverage of CG Oncology (CGON) with Overweight Recommendation

August 20, 2025 | msn.com

H.C. Wainwright Reiterates a Buy on CG Oncology (CGON), Keeps the PT

August 20, 2025 | msn.com

CG Oncology’s Bladder Cancer Drug Shows Strong Clinical Data, Drives Optimism Despite Price Target Cut

August 20, 2025 | msn.com

Piper Sandler initiates coverage of oncology companies

August 19, 2025 | msn.com

CG Oncology initiated with an Overweight at Piper Sandler

August 19, 2025 | msn.com

Q3 Earnings Estimate for CG Oncology Issued By HC Wainwright

August 16, 2025 | marketbeat.com

Cantor Fitzgerald Lowers Earnings Estimates for CG Oncology

August 15, 2025 | marketbeat.com

CG Oncology, Inc. (NASDAQ:CGON) Given Average Recommendation of "Buy" by Brokerages

August 12, 2025 | marketbeat.com

CG Oncology price target lowered to $62 from $63 at BofA

August 11, 2025 | msn.com

CG Oncology (NASDAQ:CGON) Releases Quarterly Earnings Results

August 11, 2025 | marketbeat.com

CG Oncology’s Strategic Advancements and Promising Data Reinforce Buy Rating

August 11, 2025 | tipranks.com

CG Oncology (NASDAQ:CGON) Rating Lowered to "Sell" at Wall Street Zen

August 10, 2025 | marketbeat.com

CG Oncology’s Q2 2025: Clinical Advances and Legal Wins

August 8, 2025 | tipranks.com

Buy Rating for CG Oncology, Inc. Driven by Promising Clinical Data and Strategic Advancements

August 8, 2025 | tipranks.com

Cg Oncology (CGON) Q2 Loss Widens 93%

August 8, 2025 | aol.comA

CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 8, 2025 | globenewswire.com

CG Oncology (CGON) Projected to Release Earnings on Thursday

August 7, 2025 | marketbeat.com

TD Asset Management Inc Sells 10,878 Shares of CG Oncology, Inc. (NASDAQ:CGON)

August 5, 2025 | marketbeat.com

CG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer Trial

July 31, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, ARQT, ADPT, and CGON Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$13.00 +0.37 (+2.93%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.86 -0.14 (-1.08%)

As of 08/22/2025 07:35 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Arcutis Biotherapeutics NASDAQ:ARQT

$15.98 +0.19 (+1.20%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.95 -0.03 (-0.18%)

As of 08/22/2025 07:56 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Bicycle Therapeutics NASDAQ:BCYC

$7.10 +0.01 (+0.14%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.16 +0.06 (+0.77%)

As of 08/22/2025 07:59 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

CG Oncology NASDAQ:CGON

$26.92 +0.94 (+3.62%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$26.89 -0.03 (-0.11%)

As of 08/22/2025 04:20 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time